Anifrolumab Treatment Improves Quality of Life and Decreases Systemic Corticosteroid Use in Patients with Systemic Lupus Erythematosus

The study on Anifrolumab treatment for systemic lupus erythematosus (SLE) patients revealed significant improvements in quality of life and a decrease in systemic corticosteroid use. Conducted through qualitative interviews with 14 patients and electronic medical record data from 16 patients, the research highlighted a reduction in bothersome symptoms such as fatigue, joint pain, and hair loss. Patients reported enhanced daily life activities, social interactions, and emotional well-being post-treatment. Additionally, clinical data showed decreased disease activity and improved laboratory results, supporting the subjective reports of symptom alleviation. These findings underscore the efficacy of Anifrolumab in managing SLE.